Immuneel Cell Therapy Program

What is Immuneel's Cell Therapy Program ?

For the first time, the promise of lasting remission for a few cancers such as leukemias, lymphomas and mutiple myeloma, as well as genetic disorders is on the horizon. Immuneel is committed to dramatically increase the access to transformational cell-based immunotherapies for cancer patients in India. Our purpose to develop and deliver high quality affordable cell therapies through disruptive technologies and to make India a preferred destination for advanced cancer care and treat an under-served patient population. Our facilities are designed to be globally compliant with semi-integrated, semi-automated closed cell manufacturing processes.

Our strategically located hub and decentralized model ensures delivery of quality products to our patients, regardless of their location. Our network of advisors and partners coupled with our team’s diverse experience are key enablers in our path to success in delivering our Cell Therapies. With Immuneel's Cell Therapy Program we aim to provide you an end-to-end solution of Cell therapies to you and the qualified treatment centers.

Our Products

As we seek to disrupt cancer care in India, our immediate focus is to treat blood cancers. Our first set of development programs are CAR T-cell therapies targeting single and dual receptors for adult lymphomas, adult leukemias, and childhood leukemia, in patients who have failed existing therapy. Our Research & Development center is recognized by DSIR (Department of Scientific and Industrial Research, Government of India).

Qartemi

Revolutionizing cancer care with transformative outcomes, instilling renewed hope in treatment for Relapsed / Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

View Pipeline

Our Program for CAR T-cell Therapy in India

Our program is dedicated to provide exceptional outcomes through CAR T-cell therapy.

  1. Patient Identification

    Once a patient is identified for CAR T-cell Therapy, the qualified treatment center will inform Immuneel Therapeutics based on which dates for Leukapheresis and CAR T-cell infusion will be finalized.

  2. Leukapheresis

    The patient will undergo apheresis, which involves a collection of white blood cells. The collected apheresis product will be sent to Immuneel Therapeutics for manufacturing CAR T-cells.

  3. Manufacturing

    CAR T-cells are manufactured and undergo stringent quality release prior to dispatch to treatment centers for infusion.

  4. Bridging Therapy

    Patients may require bridging therapy for disease control while the CAR T-cell product is being manufactured.

  5. Infusion

    The CAR T-cell product is delivered to the treatment center. Prior to CAR T-cell administration, the patient undergoes preparative lymphodepletion. The product should be administered using a regular infusion set (no inline filter).

  6. Short-term monitoring

    The patient is monitored closely for at least 4 weeks and side effects are promptly managed. Caregiver support is critical during this time.

  7. Long-term monitoring

    Patient undergoes periodic long-term monitoring.

Have a Question?

Our experienced team is ready to provide you with the support and guidance you need to make informed decisions about personalized cell and gene therapies.

Contact us